Literature DB >> 30022301

Rheumatology science and practice in India.

Durga Prasanna Misra1, Aman Sharma2, Vikas Agarwal3.   

Abstract

The practice of rheumatology in a country like India presents its own unique challenges, including the need to manage patients in a cost-constrained setting, where the lack of uniform government funding for healthcare merits the need to optimize the use of cheaper medicines, as well as devise innovative strategies to minimize the use of costlier drugs such as biologic disease-modifying agents. Use of immunosuppressive agents is also associated with increased risks of infectious complications, such as the reactivation of tuberculosis. In this narrative review, we provide a flavor of such challenges unique to Rheumatology practice in India, and review the published literature on the management of common rheumatic diseases from India. In addition, we critically review existing guidelines for the management of rheumatic diseases from this part of the world. We also discuss infectious etiologies of rheumatic complaints, such as leprosy, tuberculosis, and Chikungunya arthritis, which are often encountered here, and pose a diagnostic as well as therapeutic challenge for clinicians. There remains a need to identify and test more cost-effective strategies for Indian patients with rheumatic diseases, as well as the requirement for more government participation to enhance scant facilities for the treatment of such diseases as well as foster the development of healthcare services such as specialist nurses, occupational therapists and physiotherapists to enable better management of these conditions.

Entities:  

Keywords:  Cost-constrained scenario; India; Management; Rheumatology; Tropical rheumatology

Mesh:

Year:  2018        PMID: 30022301     DOI: 10.1007/s00296-018-4111-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  89 in total

1.  Chikungunya virus aches and pains: an emerging challenge.

Authors:  Arvind Chopra; V Anuradha; V Lagoo-Joshi; V Kunjir; S Salvi; M Saluja
Journal:  Arthritis Rheum       Date:  2008-09

2.  Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study.

Authors:  Sirisha Kommireddy; Srinivas Bhyravavajhala; Kishorebabu Kurimeti; Srinivasa Chennareddy; Suresh Kanchinadham; Irlapati Rajendra Vara Prasad; Liza Rajasekhar
Journal:  Rheumatology (Oxford)       Date:  2015-04-29       Impact factor: 7.580

3.  High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.

Authors:  Ajay Wanchu; Bettadpura Shamanna Suryanaryana; Shefali Sharma; Aman Sharma; Pradeep Bambery
Journal:  Int J Rheum Dis       Date:  2009-09       Impact factor: 2.454

4.  Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: Single centre experience from a large tertiary care teaching hospital in Southern India.

Authors:  Ruchika Goel; Debashish Danda; George Joseph; Raheesh Ravindran; Sathish Kumar; Visali Jayaseelan; Lakshmanan Jayaseelan; Paul Bacon
Journal:  Semin Arthritis Rheum       Date:  2017-09-30       Impact factor: 5.532

5.  Stem cell transplant in systemic sclerosis: An Indian experience.

Authors:  Velu Nair; Vivek Vasdev; Abhishek Kumar; Subramanian Shankar; Vivek Nair; Ajay Sharma
Journal:  Int J Rheum Dis       Date:  2018-02-02       Impact factor: 2.454

6.  Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study.

Authors:  Pooja Dhaon; Siddharth K Das; Ragini Srivastava; Girdhar Agarwal; Akash Asthana
Journal:  Int J Rheum Dis       Date:  2016-07-26       Impact factor: 2.454

7.  Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor.

Authors:  R K Saurenmann; J B Rose; P Tyrrell; B M Feldman; R M Laxer; R Schneider; E D Silverman
Journal:  Arthritis Rheum       Date:  2007-06

8.  Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study.

Authors:  Yashika Garg; Jatinder Singh; H S Sohal; Rajeshwari Gore; Arun Kumar
Journal:  Indian J Pharmacol       Date:  2017 Sep-Oct       Impact factor: 1.200

9.  Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.

Authors:  Padmanabha D Shenoy; Manish Bavaliya; Sujith Sashidharan; Kaveri Nalianda; Sreelakshmi Sreenath
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

Review 10.  Rheumatology in India: a Bird's Eye View on Organization, Epidemiology, Training Programs and Publications.

Authors:  Durga Prasanna Misra; Vikas Agarwal; Vir Singh Negi
Journal:  J Korean Med Sci       Date:  2016-05-10       Impact factor: 2.153

View more
  5 in total

Review 1.  Rheumatology in Egypt: back to the future.

Authors:  Tamer A Gheita; Nahla N Eesa
Journal:  Rheumatol Int       Date:  2018-11-07       Impact factor: 2.631

Review 2.  Advances in rheumatology practice in Brazil.

Authors:  Francisco Airton Castro Rocha; Joaquim Ivo Vasques Dantas Landim; Leila Nascimento da Rocha
Journal:  Rheumatol Int       Date:  2018-12-01       Impact factor: 2.631

3.  Persistent eosinophilia in rheumatoid arthritis: a prospective observational study.

Authors:  Dantis Emmanuel; Subhash Chandra Parija; Ankit Jain; Durga Prasanna Misra; Rakhee Kar; Vir Singh Negi
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

Review 4.  Rheumatology in Ukraine.

Authors:  Bohdana Doskaliuk; Olena Zimba; Roman Yatsyshyn; Volodymyr Kovalenko
Journal:  Rheumatol Int       Date:  2020-01-02       Impact factor: 2.631

Review 5.  Neglected tropical rheumatic diseases.

Authors:  Rasmi Ranjan Sahoo; Anupam Wakhlu; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2022-02-10       Impact factor: 3.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.